Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.

Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P.

J Neural Transm (Vienna). 2013 Feb;120(2):299-307. doi: 10.1007/s00702-012-0872-1. Epub 2012 Aug 10.

PMID:
22878514
2.

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S; Global Dysport Cervical Dystonia Study Group.

Parkinsonism Relat Disord. 2010 Jun;16(5):316-23. doi: 10.1016/j.parkreldis.2010.03.002. Epub 2010 Mar 31.

PMID:
20359934
3.

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.

Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL.

J Neural Transm (Vienna). 2013 Dec;120(12):1699-707. doi: 10.1007/s00702-013-1048-3. Epub 2013 Jun 19.

4.

Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.

Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD.

Clin Ther. 2007 Jul;29(7):1325-37. Review.

PMID:
17825685
5.

Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.

Laubis-Herrmann U, Fries K, Topka H.

Eur Neurol. 2002;47(4):214-21.

PMID:
12037435
6.

IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.

Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A.

J Neurol Sci. 2014 Nov 15;346(1-2):116-20. doi: 10.1016/j.jns.2014.08.004. Epub 2014 Aug 10.

7.

A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.

Rystedt A, Zetterberg L, Burman J, Nyholm D, Johansson A.

Clin Neuropharmacol. 2015 Sep-Oct;38(5):170-6. doi: 10.1097/WNF.0000000000000101.

PMID:
26366966
8.

What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.

Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G.

J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13-7.

9.

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M.

Neurology. 1999 Oct 22;53(7):1439-46.

PMID:
10534248
11.

Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.

Coleman C, Hubble J, Schwab J, Beffy JL, Picaut P, Morte C.

Int J Neurosci. 2012 Jul;122(7):358-62. doi: 10.3109/00207454.2012.668725. Epub 2012 May 11.

PMID:
22356470
12.

BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).

Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD.

Mov Disord. 1997 Sep;12(5):772-5.

PMID:
9380065
13.

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.

Mov Disord. 2005 Jul;20(7):783-91.

PMID:
15736159
14.
15.

A 17-year experience of abobotulinumtoxina in cervical dystonia.

Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E.

Int J Neurosci. 2012 Jul;122(7):354-7. doi: 10.3109/00207454.2012.665971. Epub 2012 Mar 20. Erratum in: Int J Neurosci. 2012 Dec;122(12):767.

PMID:
22329596
16.

Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group.

J Neurol Sci. 2011 Sep 15;308(1-2):103-9. doi: 10.1016/j.jns.2011.05.041. Epub 2011 Jul 18.

PMID:
21764407
17.

Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.

Jen MH, Kurth H, Iheanacho I, Dinet J, Gabriel S, Wasiak R, Jost WH.

J Med Econ. 2014 Nov;17(11):803-9. doi: 10.3111/13696998.2014.953680. Epub 2014 Aug 29.

PMID:
25155368
19.

Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.

Kazerooni R, Broadhead C.

Am J Health Syst Pharm. 2015 Feb 15;72(4):301-7. doi: 10.2146/ajhp140276.

PMID:
25631837
20.

Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.

Grosset DG, Tyrrell EG, Grosset KA.

J Rehabil Med. 2015 Feb;47(2):183-6. doi: 10.2340/16501977-1895.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk